Bladder cancer is the eighth most commonly diagnosed cancer in China. The bladder cancer therapy market is set to enter a competitive and dynamic period of rapid growth, fueled by one of the most robust drug-development pipelines in oncology. Notably, the biggest driver of market sales will be the anticipated approvals of immune checkpoint inhibitors from both multinational corporations and domestic companies; these agents will transform treatment. Biomarker-driven therapies are becoming increasingly attractive, highlighted by the development of Xian Janssen’s Balversa for patients harboring FGFR mutations, and are expected to gain approval during the forecast period, resulting in better treatment options for metastatic patients. Additionally, in view of the ongoing reforms in China’s regulatory and access and reimbursement landscape, multinational companies will be increasingly encouraged to enter the bladder cancer market.
- How large is China’s drug-treatable bladder cancer population, and how will drug-treatment rates change during the forecast period?·
- Which are the most commercially relevant drugs in China’s bladder cancer market and why? What are interviewed experts’ insights into current treatment options?·
- What are the market access considerations for key therapies in the bladder cancer pipeline in China? What sales could these agents secure in bladder cancer? What are interviewed experts’ opinions of key emerging therapies?·
- What are the key drivers and constraints in China’s bladder cancer therapy market, and how will the market evolve over the forecast period?
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 50 surveys with hematologist-oncologists as well as 25 urologists. Supported by survey data collected for this and other Clarivate research.
Diagnosed incidence of bladder cancer in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations
Annualized, 10-year, drug-level sales and patient share of key bladder cancer therapies through 2030, based on primary and secondary market research to formulate bottom-up assumptions.
Phase III / PR: 10+ drugs; Phase II: 10+ drugs; coverage of select Phase I products.
- Bladder Cancer And Upper Tract Urothelial Carcinoma - Geographic Focus: China - Bladder Cancer - China In-Depth (China)
- Bladder Cancer - China In-Depth (China)
Amardeep Singh, M.Pharm.
Amardeep Singh, M.Pharm., is a senior analyst on the China In-Depth team at Clarivate. He has more than nine years’ experience in market research and business analytics in the pharmaceutical industry, with expertise in market forecasting, brand performance analytics, benchmark and analogue analysis, primary market research, and competitive landscape. He has specialized in market research and competitive intelligence for a range of diseases, including NASH, colorectal cancer, acute myeloid leukemia, and non-Hodgkin’s lymphoma. He received his master’s degree in pharmaceutical management from the Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR) in New Delhi and his bachelor’s degree in pharmacy from Guru Gobind Singh Indraprastha University (GGSIPU), also in New Delhi.
Narendra Parihar, B.D.S., M.P.H., Senior Manager, Epidemiology. Dr Parihar is a team lead at Clarivate Epidemiology. He specializes in modelling and forecasting epidemiology patient populations across multiple indications. His primary areas of interest are cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer. His qualifications include a master’s degree in public health with specialization in health policy, economics, and finance from Tata Institute of Social Sciences Mumbai, and a bachelor’s degree in dental surgery from the Rajasthan University of Health Sciences.